Every material Form 8-K CLARIVATE PLC has filed with the SEC since October 06, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Clarivate's subsidiary, Clarivate Science Holdings Corporation, has started cash tender offers to buy back certain senior notes, subject to a $500 million aggregate cap. The offers expire November 10, 2026, with settlement expected November 13, 2026, and the filing gives no financial results.
Offers cover the 3.875% Senior Secured Notes due 2028 (up to $400 million cap, $750 million outstanding) and the 4.875% Senior Notes due 2029 (up to $100 million cap, $900 million outstanding)
2029 Notes tender consideration is fixed at $928.75 per $1,000 principal amount; 2028 Notes price is set by a fixed spread of +50 basis points over a Treasury reference yield on November 10, 2026
Citigroup Global Markets Inc. is dealer manager; Global Bondholder Services Corporation is tender and information agent
Clarivate reported third-quarter 2026 results, with continuing-operations revenue down 9.2% to $481.6 million, mainly from inorganic disposals, and organic revenue up 0.4%. The company completed the sale of its Life Sciences & Healthcare segment on October 6, 2026, for net cash proceeds of $488.4 million, and updated its full-year 2026 outlook excluding that segment, so shareholders will see a smaller revenue base and a reported net loss driven by a non-cash impairment.
Q3 net loss including discontinued operations was $80.8 million, or $0.13 per diluted share, versus a net loss of $28.3 million, or $0.04, a year earlier, driven by a $62.2 million non-cash goodwill impairment
Adjusted diluted EPS was $0.21 versus $0.18 a year earlier; Adjusted EBITDA including discontinued operations was $245.3 million versus $252.4 million
Full-year 2026 outlook (continuing operations): revenue $1.965 billion to $1.985 billion, adjusted diluted EPS $0.73 to $0.77, free cash flow $320 million to $340 million
Clarivate completed the sale of its Life Sciences & Healthcare segment to an affiliate of Altaris, LLC on October 6, 2026, for a total value of $600 million, according to the company's press release. The company says it will use the proceeds to reduce debt, and it will update its full year 2026 guidance to reflect the divestiture when it reports third quarter results on November 3, 2026.
Cash paid at closing was $500 million, subject to customary adjustments, plus a $75 million unsecured senior note issued by an Altaris affiliate.
A further $25 million of deferred consideration is payable later, no earlier than the conditions tied to transition services and no later than January 31, 2028.
Henry Levy, President of Life Sciences & Healthcare, left his subsidiary role at closing under a separation agreement tied to a retention agreement.
Clarivate will file pro forma financial statements by October 13, 2026, and report third quarter 2026 results on November 3, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CLARIVATE PLC filing is on SEC EDGAR ↗. 8-K briefs of other companies →